文章摘要

参考文献/References:

1 Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48.
2 吴国明, 钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
3 王园, 杨懿, 牟云飞, 等. 可切除非小细胞肺癌患者术后奥西替尼靶向治疗分析[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(5): 657-660.
4 Vinod SK, Hau E. Radiotherapy treatment for lung cancer: Current status and future directions[J]. Respirology, 2020,(25 Suppl 2): 61-71.
5 Chow A, Perica K, Klebanoff CA, et al. Clinical implications of T cell exhaustion for cancer immunotherapy[J]. Nat Rev Clin Oncol, 2022, 19(12): 775-790.
6 Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers[J]. Int J of Mol Sci, 2014, 15(1): 927-943.
7 Camphausen K, Moses MA, Beecken WD, et al. Radiation therapy to a primary tumor accelerates metastatic growth in mice[J]. Cancer Res, 2001, 61(5): 2207-2211.
8 Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer[J]. N Engl J Med, 2022, 386(21): 1973-1985.
9 Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage ⅠB-ⅢA non-small-cell lung cancer(IMpower010): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet, 2021, 398(10308): 1344-1357.
10 O'Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage ⅠB-ⅢA non-small-cell lung cancer(PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial[J]. Lancet Oncol, 2022, 23(10): 1274-1286.
11 Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer[J]. N Engl J Med, 2023, 389(18): 1672-1684.
12 Lu S, Zhang W, Wu L, et al. Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: The neotorch randomized clinical trial[J]. JAMA, 2024, 331(3): 201-211.
13 Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer[J]. N Engl J Med, 2023, 389(6): 491-503.
14 Yue DS, Wang WX, Liu HX, et al. RATIONALE-315: Event-free survival(EFS)and overall survival(OS)of neoadjuvant tislelizumab(TIS)plus chemotherapy(CT)with adjuvant TIS in resectable non-small cell lung cancer(NSCLC)[J]. Ann Oncol, 2024, 35(Suppl 3): 322-323.
15 Peters S, Kim AW, Solomon B, et al. IMpower030: Phase Ⅲ study evaluating neoadjuvant treatment of resectable stage Ⅱ-ⅢB non-small cell lung cancer(NSCLC)with atezolizumab(atezo)+ chemotherapy[J]. Ann Oncol, 2019, 30(Suppl 2): 1130.
16 Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials[J]. Lancet Oncol, 2015, 16(6): 630-637.
17 Chang JY, Lin SH, Dong W, et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial[J]. Lancet, 2023, 402(10405): 871-881.
18 Robinson CG, Xing L, Tanaka H,et al. Phase 3 study of durvalumab with SBRT for unresected stage Ⅰ/Ⅱ, lymph-node negative NSCLC(PACIFIC-4/RTOG3515)[J]. J Clin Oncol, 2023, 41(16_suppl): TPS8607-TPS8607.
19 Altorki NK, McGraw TE, Borczuk AC, et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial[J]. Lancet Oncol,2021, 22(6): 824-835.
20 Jabbour SK, Houghton B, Robinson AG, et al. KEYNOTE-867: Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy(SBRT)with or without pembrolizumab in patients with unresected stage Ⅰ or Ⅱ non-small cell lung cancer(NSCLC)[J]. Int J Radiat Oncol Biol Phys, 2022, 40(16_suppl): TPS8597-TPS8597.
21 Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. J Clinl Oncol, 2022, 40(12): 1301-1311.
22 Zhou Q, Chen M, Wu G, et al. Gemstone-301: A phase Ⅲ clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable(stage Ⅲ)non-small cell lung cancer(NSCLC)who did not have progressed after prior concurrent/sequential chemoradiotherapy[J]. Transl Lung Cancer Res, 2020, 9(5): 2008-2015.
23 Zhou Q, Chen M, Jiang O, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage Ⅲ non-small-cell lung cancer in China(GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial[J]. Lancet Oncol, 2022, 23(2): 209-219.
24 Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. N Engl JMed, 2017, 377(20): 1919-1929.
25 Reck M, Lee KH, Frost N, et al. Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy(cCRT)for unresectable, locally advanced, stage Ⅲ NSCLC[J]. J Clin Oncol. 2022, 40(16_suppl): 8508.
26 Bradley JD, Sugawara S, Lee KHH, et al. Durvalumab in combination with chemoradiotherapy for patients with unresectable stage Ⅲ NSCLC: Final results from PACIFIC-2[J]. Ann Oncol, 2024, 9(suppl_3): 1-12.
27 Horndalsveen H, Alver TN, Dalsgaard AM, et al. Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses-the ComIT-1 trial[J]. Mol Oncol, 2023, 17(3): 487-498.
28 Ding P, Huang Y, Tong F, et al. MA09.04 First-line PD-1 inhibitors and chemotherapy combined with or without radiotherapy in advanced non-small-cell lung cancer[J]. J Thorac Oncol, 2022, 17(Suppl 9): S75.
29 Patel JD, Bestvina CM, Karrison T, et al. Randomized phase I trial to evaluate concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage Ⅳ non-small cell lung cancer(COSINR Study)[J]. J Clin Oncol, 2020, 38(15_suppl): 9616.
30 Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial[J]. Lancet Oncol, 2015, 16(7): 795-803.
31 Yin L, Xue J, Li R, et al. Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2020, 108(1): 212-224.
32 Kong Y, Chen R, Xu M, et al. Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study(PRaG5.0 study)[J]. BMJ Open, 2024, 14(3): e075642.
33 Moghaddasi L, Reid P, Bezak E, et al. Radiobiological and treatment-related aspects of spatially fractionated radiotherapy[J]. Int J Mol Sci, 2022, 23(6): 3366.
34 Bertho A, Iturri L, Prezado Y. Radiation-induced immune response in novel radiotherapy approaches FLASH and spatially fractionated radiotherapies[J]. Int Rev Cell Mol Biol, 2023, 376: 37-68.
35 Li J, Zhao Z, Du G, et al. Safety and efficacy of pulsed low-dose rate radiotherapy for local recurrent esophageal squamous cell carcinoma after radiotherapy: Study protocol for a prospective multi-center phase Ⅱ trial[J]. Medicine(Baltimore), 2019, 98(26): e16176.
36 Guan J, Sun K, Guerrero CA, et al. A phase 2 study of in situ oncolytic virus therapy and stereotactic body radiation therapy followed by pembrolizumab in metastatic non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2024, 118(5): 1531-1540.
37 Kharouta MZ, Gross AJ, Kelley KD, et al. Analysis of patterns of care and benefit of thoracic radiotherapy for patients with stage IV NSCLC in the immunotherapy-era from a national hospital-based registry[J]. Int J Radiat Oncol Biol Phys, 2021, 111(3s): e441-442.
38 Wang J, Zhou C, Yao W,et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer(CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2022, 23(6): 739-747.
39 Chen D, Gao A, Huang W, et al. Updated safety and efficacy results of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer(ES-SCLC)from a phase Ⅱ trial[J]. J Clin Oncol, 2023, 41(16_suppl): 8580.
40 Suresh K, Naidoo J, Lin CT, et al. Immune checkpoint immunotherapy for non-small cell lung cancer: Benefits and pulmonary toxicities[J]. Chest, 2018, 154(6): 1416-1423.
41 Lemiale V, Meert AP, Vincent F, et al. Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know? [J]. Annals Intensive Care, 2019, 9(1): 25.
42 Suresh K, Voong KR, Shankar B, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: Incidence and risk factors[J]. J Thorac Oncol, 2018, 13(12): 1930-1939.
43 Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and Meta-analysis of trials[J]. Chest, 2017, 152(2): 271-281.
44 Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC[J]. N Engl JMed, 2018, 379(24): 2342-2350.
45 Nakamichi S, Kubota K, Misumi T,et al. A phase Ⅱ study of durvalumab(MEDI4736)immediately after completion of chemoradiotherapy in unresectable stage Ⅲ non-small cell lung cancer: TORG1937(DATE study)[J]. Clin Cancer Res, 2024, 30(6): 1104-1110.
46 Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non small-cell lung cancer treated with pembrolizumab: Results from the phase I KEYNOTE-001 atudy[J]. J Clin Oncol, 2019, 37(28): 2518-2527.
47 Theelen W, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: Results of the PEMBRO-RT phase 2 randomized clinical trial[J]. JAMA oncology, 2019, 5(9): 1276-1282.
48 Bauml JM, Mick R, Ciunci C, et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: A phase 2 trial[J]. JAMA oncology, 2019, 5(9): 1283-1290.
49 Wegner RE, Abel S, Hasan S, et al. Time from stereotactic body radiotherapy to immunotherapy as a predictor for outcome in metastatic non small cell lung cancer[J]. J Clin Oncol, 2019, 37(15_suppl): 9024-9024.
50 Zhao X, Li J, Zheng L, et al. Immune response on optimal timing and fractionation dose for hypofractionated radiotherapy in non-small-cell lung cancer[J]. Front Mol Biosci. 2022, 9: 786864.
51 Mole RH. Whole body irradiation; radiobiology or medicine? [J]. Br J Radiol,1953, 26(305): 234-241.
52 Ngwa W, Irabor OC, Schoenfeld JD, et al. Using immunotherapy to boost the abscopal effect[J]. Nat Rev Cancer, 2018, 18(5): 313-322.
53 Theelen W, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials[J]. Lancet Respir Med, 2021, 9(5): 467-475.
54 Liu Z, Xu T, Chang P, et al. Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis[J]. Front Pharmacol, 2023, 14: 1064227.
55 Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects[J]. Nat Rev Clin Oncol, 2019, 16(2): 123-135.
56 Golden EB, Demaria S, Schiff PB, et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer[J]. Cancer Immunol Res,2013, 1(6): 365-372.
57 Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J]. Nature,2015, 520(7547): 373-377.
58 Durante M, Reppingen N, Held KD. Immunologically augmented cancer treatment using modern radiotherapy[J]. Trends Mol Med, 2013, 19(9): 565-582.

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

文章信息/Info

参考文献/References:

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics